Zhi Tong Cai Jing·2026-01-13 02:22Group 1 - The CRO concept stocks have shown significant gains, with WuXi AppTec rising by 8.48% to HKD 120.2, and other companies like Kelun Pharmaceutical and Tigermed also experiencing notable increases [1] - WuXi AppTec announced an expected annual revenue of CNY 45.456 billion, representing a year-on-year growth of 15.84%, with a notable increase in adjusted net profit by approximately 41.33% to CNY 14.957 billion [1] - The company has revised its full-year performance guidance twice within a year, increasing its revenue forecast from CNY 42.5-43.5 billion to CNY 43.5-44 billion, indicating strong business momentum [1] Group 2 - Zhongtai Securities predicts that the CRO and CDMO sectors will see a gradual recovery in demand due to multiple factors, including the onset of overseas interest rate cuts in Q4 2024 and significant policy developments in 2025 [2] - The firm suggests that the sector is poised for a "Davis Double Play," where both profitability and valuation are expected to improve, recommending investment opportunities in this area [2] - Industrial trends indicate an upward price movement for clinical project costs and sustained customer demand, with expectations for CRO performance to enter a recovery cycle by 2026 [2]